• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $PALI

    Palisade Bio Inc.

    Subscribe to $PALI
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Palisade Bio, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress, such as results from reduced blood flow to the intestine, infections, and surgery. The company was founded in 2005 and is based in Carlsbad, California.

    IPO Year:

    Exchange: NASDAQ

    Website: palisadebio.com

    Peers

    $BXRX
    $CABA
    $GOSS
    $INMB
    $PASG
    $PRVB
    $SESN
    $XOMA
    $ACET
    $TIL
    $GRPH

    Recent Analyst Ratings for Palisade Bio Inc.

    DatePrice TargetRatingAnalyst
    2/2/2022$5.00Buy
    Ladenburg Thalmann
    8/31/2021$7.00Buy
    Maxim Group
    See more ratings

    Palisade Bio Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ladenburg Thalmann initiated coverage on Palisade Bio with a new price target

      Ladenburg Thalmann initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $5.00

      2/2/22 7:38:44 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Maxim Group initiated coverage on Palisade Bio with a new price target

      Maxim Group initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $7.00

      8/31/21 8:02:44 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Palisade Bio Inc. SEC Filings

    See more
    • Palisade Bio Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - PALISADE BIO, INC. (0001357459) (Filer)

      5/2/25 4:11:24 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-K filed by Palisade Bio Inc.

      10-K - PALISADE BIO, INC. (0001357459) (Filer)

      3/24/25 4:20:12 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B3 filed by Palisade Bio Inc.

      424B3 - PALISADE BIO, INC. (0001357459) (Filer)

      12/17/24 5:30:00 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B3 filed by Palisade Bio Inc.

      424B3 - PALISADE BIO, INC. (0001357459) (Filer)

      12/17/24 5:29:46 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B3 filed by Palisade Bio Inc.

      424B3 - PALISADE BIO, INC. (0001357459) (Filer)

      12/17/24 5:29:28 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Palisade Bio Inc.

      EFFECT - PALISADE BIO, INC. (0001357459) (Filer)

      12/17/24 12:15:08 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Palisade Bio Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

      8-K - PALISADE BIO, INC. (0001357459) (Filer)

      12/16/24 4:00:16 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B5 filed by Palisade Bio Inc.

      424B5 - PALISADE BIO, INC. (0001357459) (Filer)

      12/13/24 10:31:39 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form POS AM filed by Palisade Bio Inc.

      POS AM - PALISADE BIO, INC. (0001357459) (Filer)

      12/13/24 9:57:40 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Palisade Bio Inc.

      EFFECT - PALISADE BIO, INC. (0001357459) (Filer)

      12/13/24 12:15:08 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Palisade Bio Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more

    Palisade Bio Inc. Leadership Updates

    Live Leadership Updates

    See more

    Palisade Bio Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    Palisade Bio Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases

      Two posters presented at Digestive Disease Week (DDW) 2025 Preclinical results indicate that PALI-2108 effectively modulates inflammatory pathways in the colon, promoting a favorable immune response Company advancing Phase 1a/b study of PALI-2108 and has demonstrated a favorable safety profile in single-ascending-dose cohorts Carlsbad, CA, May 06, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade", "Palisade Bio", or the "Company"), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced the presentation of positive preclinical data from

      5/6/25 8:30:00 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Palisade Bio's AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit

      Carlsbad, CA, May 01, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade", "Palisade Bio", or the "Company"), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it has been selected to give an oral presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit being held May 13–15, 2025 in Boston, MA. Details of the oral presentation are as follows: Session: Advancing AI-Driven Diagnostics & Enhancing Patient Monitoring to Personalize Treatment Decisions & Improve Long-Term Patient OutcomesTitle: Improving

      5/1/25 8:30:00 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108

      Sustained positive preliminary data from all completed single ascending dose (SAD) cohorts, multiple ascending dose (MAD) cohorts, and food effects crossover, further supporting the safety and tolerability of PALI-2108 No serious adverse events (SAEs) or treatment-emergent adverse events (TEAEs) related to laboratory values or EKGs observed to date Screening for Phase 1b UC cohort ongoing; On track to report topline data in the first half of 2025 Carlsbad, CA, April 09, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade", "Palisade Bio", or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for patients with autoimmune,

      4/9/25 8:30:00 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108

      Positive preliminary data from all five single ascending dose (SAD) cohorts and first three completed multiple ascending dose (MAD) cohorts support safety and tolerability of PALI-2108 No serious adverse events (SAEs) and no treatment-emergent adverse events (TEAEs) related to laboratory values or EKGs seen to date On track to report topline data in first half of 2025 Carlsbad, CA, March 14, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade", "Palisade Bio", or the "Company"), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today provided an upda

      3/14/25 8:30:00 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025

      PALI-2108, a Colon-Specific PDE4 Inhibitor Prodrug, Abstract was Rated in the Top 10% of all AGA Abstracts Selected for Poster Presentation at DDW Carlsbad, CA, March 12, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade", "Palisade Bio", or the "Company"), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it has been selected to present data from its lead program PALI-2108 for the treatment of ulcerative colitis at Digestive Disease Week® (DDW) 2025 being held May 3–6, in San Diego, California. Participation details are as foll

      3/12/25 8:30:00 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Palisade Bio Participates in Virtual Investor "What This Means" Segment

      Dr. Joerg Heyer, Head of Translational Science and Medicine of Palisade Bio highlights preclinical data for lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC) Carlsbad, CA, March 04, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade", "Palisade Bio", or the "Company"), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced the release of a Virtual Investor "What This Means" segment. As part of this segment, Dr. Heyer discussed the Company's positive preclinical data for its lead product candidate, PALI-2108, w

      3/4/25 8:30:00 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada's SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC)

      Company through its co-development partner, Giiant Pharma, Inc. ("Giiant"), receives funding from Canadian Scientific Research and Experimental Development (SR&ED) Tax Credit Program for PALI-2108 Ongoing progress of Palisade Bio's Phase 1a/b UC study of PALI-2108 with topline data expected in the first half of 2025 Carlsbad, CA, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade", "Palisade Bio", or the "Company"), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced the receipt of CAD$1.39 million Canadian SR&ED credits for re

      2/20/25 8:45:00 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Palisade Bio, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference

      On-demand video webcast now available here  Carlsbad, CA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade", "Palisade Bio", or the "Company"), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced it participated in the Virtual Investor "Top 5 for ‘25" On-Demand Conference. As part of the event, JD Finley, Chief Executive Officer of Palisade Bio, presented the top five reasons of why he believes the investment community and industry colleagues should pay attention to the Company in 2025.  The on-demand video webcast is now ac

      2/19/25 9:00:00 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis

      Data presented at the 2025 Crohn's and Colitis Congress  PALI-2108 demonstrated to effectively reduce colitis symptoms in DSS mouse model without CNS toxicity associated with systemic exposure Company advancing Phase 1a/b study of PALI-2108 and has demonstrated a favorable safety profile in single-ascending-dose cohorts Carlsbad, CA, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.  (NASDAQ:PALI) ("Palisade", "Palisade Bio", or the "Company"), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced the presentation of positive preclinical data from PAL

      2/10/25 8:45:00 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Palisade Bio Selected for Poster Presentation at the 2025 Crohn's & Colitis Congress

      Carlsbad, CA, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade", "Palisade Bio", or the "Company"), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that its abstract has been accepted for poster presentation at the Crohn's & Colitis Congress being held February 6-8, 2025 in San Francisco, CA. Details of the poster presentation are as follows: Session: Poster and Exhibition Hall ReceptionPoster Title: PALI-2108, a Colon-Specific PDE4B Inhibitor Prodrug is Activated in the Colon and Reduces Ulcerative Colitis Symptoms in an

      1/29/25 8:45:00 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board

      Carlsbad, CA, Dec. 17, 2024 (GLOBE NEWSWIRE) --  Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade," "Palisade Bio" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for patients with autoimmune, inflammatory, and fibrotic diseases, today announced the appointment of Brian G. Feagan, MD, FRCPC, to its Clinical Advisory Board. Dr. Feagan is a distinguished gastroenterologist with over 30 years of experience in the design, conduct, and execution of large-scale randomized controlled trials (RCTs) for Crohn's disease (CD) and ulcerative colitis (UC). He has served as Principal Investigator in more than 140 multi-center RCTs and has dedicated mu

      12/17/24 8:30:00 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Palisade Bio Appoints Margery Fischbein to its Board of Directors

      Wall Street and biotech industry veteran with expertise across corporate finance, business development, M&A, licensing, and strategic alliance transactions, globally Carlsbad, CA, May 07, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade", "Palisade Bio" or the "Company"), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced it has appointed Margery Fischbein to its Board of Directors. Ms. Fischbein is a highly experienced healthcare investment banker and accomplished biotechnology industry executive. "We are excited to welcome Ma

      5/7/24 8:30:00 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Correction Notice of Palisade Bio's Press Release Announcing the Appointment of Clinical Advisory Board Members

      Carlsbad, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.  (NASDAQ:PALI) ("Palisade" or the "Company"), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced a correction to its press release originally issued on February 8, 2024, announcing the appointments of Bruce Sands, MD, MS and Florian Rieder, MD to its Clinical Advisory Board (CAB). In the original press release, it was incorrectly stated that the PALI-2108 development program was on track to commence a Phase 1 clinical study next year. The Company reiterates its guidance that the PALI-2108 Phase 1 clinical study is on track to launch in 20

      2/8/24 2:40:00 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Palisade Bio Announces Formation of Clinical Advisory Board with Appointments of Preeminent Key Opinion Leaders

      Bruce Sands, MD, MS., Dr. Burrill B. Crohn Professor of Medicine, Icahn School of Medicine at Mount Sinai and System Chief, Division of Gastroenterology, Mount Sinai Health SystemFlorian Rieder, MD, Associate Staff in the Department of Gastroenterology, Hepatology, and Nutrition, as well as an Investigator in the Department of Pathobiology at the Cleveland Clinic Carlsbad, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced the appointments of Bruce Sands, MD, MS and Florian Rieder, MD to its Clinic

      2/8/24 8:05:00 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Palisade Bio Appoints GI Clinical Expert and Biotech Entrepreneur Mitchell Jones, M.D., Ph.D. as Chief Medical Officer

      Announces Awarding of Inducement Grant to New Chief Medical Officer Carlsbad, CA, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the appointment of Mitchell Jones, M.D., Ph.D., as Chief Medical Officer. Dr. Jones has a proven track record of successfully developing oral biotherapeutics and locally acting immunomodulating therapeutics designed to act locally within the gastrointestinal tract, including for inflammatory bowel disease. Throughout his career, Dr. Jones has established a reputation for not on

      9/11/23 8:35:00 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CARsgen Appoints Richard John Daly as the President of CARsgen Therapeutics Corporation

      SHANGHAI and DURHAM, N.C., Jan. 17, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company mainly focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced today the appointment of Richard John Daly ("Mr. Daly") as the President of CARsgen Therapeutics Corporation, a subsidiary of the Company in the United States. Mr. Daly will report to Dr. Zonghai Li, Founder, Chairman of the Board, CEO, CSO of CARsgen Therapeutics Holdings Limited. Mr. Daly will lead the CARsgen U.S. team for the international business activities of CARsgen outside of China, including clinical development, CMC operation, busin

      1/17/22 8:50:00 AM ET
      $BYSI
      $CPRX
      $OPNT
      $PALI
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • SEC Form SC 13G filed by Palisade Bio Inc.

      SC 13G - PALISADE BIO, INC. (0001357459) (Subject)

      11/14/24 3:35:13 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Palisade Bio Inc. (Amendment)

      SC 13G/A - PALISADE BIO, INC. (0001357459) (Subject)

      2/14/24 2:54:03 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Palisade Bio Inc. (Amendment)

      SC 13G/A - PALISADE BIO, INC. (0001357459) (Subject)

      2/13/24 8:10:04 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Palisade Bio Inc. (Amendment)

      SC 13G/A - PALISADE BIO, INC. (0001357459) (Subject)

      2/9/24 4:03:14 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Palisade Bio Inc. (Amendment)

      SC 13G/A - PALISADE BIO, INC. (0001357459) (Subject)

      2/6/24 10:29:39 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Palisade Bio Inc.

      SC 13G - PALISADE BIO, INC. (0001357459) (Subject)

      9/15/23 4:42:46 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Palisade Bio Inc.

      SC 13G - PALISADE BIO, INC. (0001357459) (Subject)

      9/15/23 4:30:15 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Palisade Bio Inc.

      SC 13G - PALISADE BIO, INC. (0001357459) (Subject)

      2/14/23 1:14:52 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Palisade Bio Inc. (Amendment)

      SC 13G/A - PALISADE BIO, INC. (0001357459) (Subject)

      2/14/23 12:26:09 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Palisade Bio Inc. (Amendment)

      SC 13G/A - PALISADE BIO, INC. (0001357459) (Subject)

      2/13/23 4:34:58 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Jones Mitchell Lawrence

      4 - PALISADE BIO, INC. (0001357459) (Issuer)

      2/13/25 5:58:18 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by CEO, CFO Finley John David

      4 - PALISADE BIO, INC. (0001357459) (Issuer)

      2/13/25 5:56:42 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Wei Binxian converted options into 388 units of Comon Stock, increasing direct ownership by 83% to 855 units (SEC Form 4)

      4 - PALISADE BIO, INC. (0001357459) (Issuer)

      11/22/24 4:00:10 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Williams Donald Allen converted options into 388 units of Comon Stock, increasing direct ownership by 114% to 728 units (SEC Form 4)

      4 - PALISADE BIO, INC. (0001357459) (Issuer)

      11/22/24 4:00:10 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Wei Binxian

      4 - PALISADE BIO, INC. (0001357459) (Issuer)

      7/15/24 8:19:02 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Fischbein Margery B.

      4 - PALISADE BIO, INC. (0001357459) (Issuer)

      7/15/24 8:13:20 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Williams Donald Allen

      4 - PALISADE BIO, INC. (0001357459) (Issuer)

      7/15/24 8:10:24 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Wei Binxian converted options into 465 units of Comon Stock, increasing direct ownership by 23,250% to 467 units (SEC Form 4)

      4 - PALISADE BIO, INC. (0001357459) (Issuer)

      6/12/24 9:41:55 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Williams Donald Allen converted options into 340 units of Comon Stock (SEC Form 4)

      4 - PALISADE BIO, INC. (0001357459) (Issuer)

      6/12/24 9:40:23 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Finley John David converted options into 7,068 shares and covered exercise/tax liability with 2,033 shares, increasing direct ownership by 60% to 13,472 units (SEC Form 4)

      4 - PALISADE BIO, INC. (0001357459) (Issuer)

      5/30/24 7:44:32 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Palisade Bio Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Williams Donald Allen bought $4,863 worth of Comon Stock (1,000 units at $4.86) (SEC Form 4)

      4 - PALISADE BIO, INC. (0001357459) (Issuer)

      5/29/24 3:47:14 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Finley John David bought $4,810 worth of shares (1,000 units at $4.81), increasing direct ownership by 13% to 8,437 units (SEC Form 4)

      4 - PALISADE BIO, INC. (0001357459) (Issuer)

      5/28/24 6:02:01 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Finley John David bought $4,692 worth of shares (10,000 units at $0.47), increasing direct ownership by 13% to 84,649 units (SEC Form 4)

      4 - PALISADE BIO, INC. (0001357459) (Issuer)

      2/7/24 8:30:10 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Finley John David bought $5,590 worth of shares (10,000 units at $0.56), increasing direct ownership by 15% to 74,649 units (SEC Form 4)

      4 - PALISADE BIO, INC. (0001357459) (Issuer)

      2/1/24 8:30:26 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Williams Donald Allen bought $6,050 worth of shares (10,000 units at $0.60) (SEC Form 4)

      4 - PALISADE BIO, INC. (0001357459) (Issuer)

      2/1/24 8:30:23 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Williams Donald Allen bought $10,800 worth of shares (20,000 units at $0.54) (SEC Form 4)

      4 - PALISADE BIO, INC. (0001357459) (Issuer)

      9/29/23 9:25:18 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Finley John David bought $8,088 worth of shares (15,000 units at $0.54), increasing direct ownership by 53% to 43,394 units (SEC Form 4)

      4 - PALISADE BIO, INC. (0001357459) (Issuer)

      9/29/23 9:21:44 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Palisade Bio Inc. Financials

    Live finance-specific insights

    See more
    • Palisade Bio (Nasdaq: PALI) Announces Analysis Demonstrating LB1148 Reduced the Extent and Severity of Post-Surgical Intraabdominal Adhesions by 93%

      Data from Pooled-Analysis of Enteral Protease Inhibitor LB1148 Demonstrated 72% Reduction in the Risk of Adhesion Formation in Patients Undergoing Bowel Resection Surgery Company to Host Conference Call on Wednesday, March 16, 2022, at 8:30 a.m. EDT CARLSBAD, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, announced data from a Pooled-Analysis of Studies LBS-IST-POI-101 and LBS-POI-201-CN (PROFILE-CN.) These data are featured today at the Next Big Thing session of the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) 202

      3/16/22 8:00:00 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care